Financial insights of VTAK

MyFinsight

For the quarter ending 2026-03-31, VTAK made $432K in revenue. -$3,041K in net income. Net profit margin of -703.94%.

Income Statement	2026-03-31	2025-12-31	2025-09-30	2025-06-30
Revenues	432	-	-	-
Product	31	-	-	-
Revenues	-	238	226	212
Service	11	-	-	-
Total cost of revenues	42	20	18	14
Gross profit	390	218	208	198
Selling, general and administrative	2,559	2,756	2,953	2,881
Research and development	149	328	276	155
Acquired in-process research and development	0	0	0	1,848
Loss on impairment of intangible assets	-	6,995	-	-
Total operating expenses	2,708	10,079	3,229	4,884
Operating loss	-2,318	-9,861	-3,021	-4,686
Interest income	2	3	10	3
Interest expense-Nonrelated Party	76	-10*	35	-
Interest expense-Service	-	-	-	67
Interest expense-Related Party	43	42*	48	-
Change in fair value of royalties payable due to related parties	0	7,813	726	-1,667
Change in fair value of convertible notes payable	-	1*	-	-
Loss on debt extinguishment	-	-3,253*	-	-
Change in fair value of minority equity interest	-2,302	-	-	-
Net loss on trading debt securities	-	-739*	107	10
Change in fair value of deferred consideration	2,877	-	-	-
Other expenses, net	-5	7*	-5	-1
Total other income (expense), net	453	3,799	755	-1,722
Loss from operations before income tax benefit	-1,865	-6,062	-2,266	-6,408
Income tax benefit	-175	-214	78	-950
Net loss	-1,690	-5,627*	-2,344	-5,458
Less net gain attributable to non-controlling interest	-9	151*	-93	-349
Net loss attributable to catheter precision, inc	-1,681	-5,778	-2,251	-5,109
Deemed dividend on warrant inducement offer	1,360	0	-	-
Net loss attributable to catheter precision, inc. common stockholders	-3,041	-5,778	-	-

Basic EPS	-1.39	-5.347	-1.7	-0.38
Basic Average Shares	2,191,831	1,080,617*	1,320,554	13,336,088

Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.